1. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
   Sílvia Cufí et al, 2012, Oncotarget CrossRef
2. Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
   Sílvia Cufí et al, 2012, Oncotarget CrossRef
3. Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands
   Devin L. Wakefield et al, 2023, Frontiers in Medicine CrossRef
4. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer
   Callie R. Merry et al, 2016, Oncotarget CrossRef
5. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
   Begoña Martin-Castillo et al, 2015, Oncotarget CrossRef
6. Metformin: Multi-faceted protection against cancer
   Sonia Del Barco et al, 2011, Oncotarget CrossRef
7. Disabling the Nuclear Translocalization of RelA/NF-κB by a Small Molecule Inhibits Triple-Negative Breast Cancer Growth
   Hirotaka Kanzaki et al, 2021, Breast Cancer: Targets and Therapy CrossRef
8. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
   Begoña Martin-Castillo et al, 2015, Oncotarget CrossRef
9. Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts
   Yanina Dockx et al, 2021, Molecular Imaging CrossRef